NasdaqGS:ACLXBiotechs
Reassessing Arcellx (ACLX) Valuation After Wells Fargo’s Positive CAR‑T Coverage Launch
Wells Fargo just launched coverage on Arcellx (ACLX), spotlighting its experimental CAR T therapy for multiple myeloma as a potential future treatment pillar, and investors are now reassessing what the stock might be worth.
See our latest analysis for Arcellx.
The upbeat coverage comes after a choppy stretch, with Arcellx posting a steep double digit year to date share price loss but still delivering a strong three year total shareholder return. This suggests momentum is pausing rather than...